Market Research Logo

Medical Affairs Reputations: Multiple Sclerosis (EU5) 2018

Medical Affairs Reputations: Multiple Sclerosis (EU5) 2018

Introduction

Close rivalries among European multiple sclerosis medical affairs teams. Will your team come out on top?

In Europe, one multiple sclerosis medical affairs team leads the way in terms of interaction frequency and overall quality of interactions, but there’s room for improvement in other areas. The 150 neurologists from the EU5 markets (France, Germany, Italy, Spain and the UK) we polled provide insights on several medical affairs teams, and opinions are mixed. Improvement in at least one specific area is needed, but are those targeted improvements enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: Multiple Sclerosis (EU5). Comparing 11 major multiple sclerosis treatments from Sanofi, Bayer, Biogen, Teva, Novartis, and Merck Group, this report reveals:

  • How neurologists rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important.
  • How, and how often neurologists want to meet with your team.
  • What you can do to improve your medical affairs services.
That’s actionable information you can use to turn your team into one that doctors rely on.

Reasons to Purchase

Top Takeaways
  • A three horse race at the top, but all to play for. Three teams are neck and neck at the top in terms of overall quality of interactions, a chasing pack of 8 brands is separated by only 4 points, suggesting small changes could have a huge impact on who comes out on top.
  • Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions.
  • Physician interaction rates are high. In the past six months, 3 teams have interacted with more than 70 percent of doctors surveyed, and even the least active teams saw over 55 percent of them.
  • Doctors want to see teams in-person and not too often. The report reveals how, and how frequently your team should engage, and the relative importance of digital channels to your medical affairs strategy.
Insight into Medical Affairs Teams for 11 MS Treatments
  • Aubagio (teriflunomide; Sanofi)
  • Avonex (interferon beta-1a; Biogen)
  • Betaferon (interferon beta-1b; Bayer)
  • Copaxone (glatiramer acetate; Teva)
  • Gilenya (fingolimod; Novartis)
  • Lemtrada (alemtuzumab; Sanofi/Genzyme)
  • Mavenclad (cladribine; Merck Group)
  • Plegridy (peginterferon beta-1a; Biogen)
  • Rebif (interferon beta-1a; Merck Serono)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Tysabri (natalizumab; Biogen)
A Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 11 medical affairs teams—answering important questions like:

What do physicians need?
  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?
Does your medical affairs team deliver?
  • How memorable are your team’s interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition—in each area, and overall?
What needs improvement?
  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?
Based on Interviews with Practicing Doctors

We surveyed 150 neurologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents:
  • Have been practicing for between 3 and 35 years
  • See at least 5 patients a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product’s medical affairs team in the past 6 months.
We conducted the survey between May 3-11, 2018.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


1. Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary
2. Current Status of Interactions with Different Medical Affairs Teams
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. Preferred Interaction Media, Frequency, and Suggestions for Improvement
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report